Majima M - Search Results

1

Nitric oxide generated by iNOS reduces deformability of Lewis lung carcinoma cells.

Igawa S, Hayashi I, Tanaka N, Hiruma H, Majima M, Kawakami T, Hirose M, Masuda N, Kobayashi H. Igawa S, et al. Among authors: majima m. Cancer Sci. 2004 Apr;95(4):342-7. doi: 10.1111/j.1349-7006.2004.tb03213.x. Cancer Sci. 2004. PMID: 15072593 Free PMC article.

2

Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants.

Majima M, Isono M, Ikeda Y, Hayashi I, Hatanaka K, Harada Y, Katsumata O, Yamashina S, Katori M, Yamamoto S. Majima M, et al. Jpn J Pharmacol. 1997 Oct;75(2):105-14. doi: 10.1254/jjp.75.105. Jpn J Pharmacol. 1997. PMID: 9414024 Free article.

3

Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.

Nakajima S, Majima M, Ito H, Hayashi I, Yajima Y, Katori M. Nakajima S, et al. Among authors: majima m. Int J Tissue React. 1998;20(2):45-56. Int J Tissue React. 1998. PMID: 9638501

4

Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.

Katori M, Majima M, Hayashi I. Katori M, et al. Among authors: majima m. Biol Res. 1998;31(3):143-9. Biol Res. 1998. PMID: 9830501 Review.

5

Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists.

Hayashi I, Majima M. Hayashi I, et al. Among authors: majima m. Br J Pharmacol. 1999 Jan;126(1):197-204. doi: 10.1038/sj.bjp.0702296. Br J Pharmacol. 1999. PMID: 10051136 Free PMC article.

6

Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.

Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Ito H, et al. Among authors: majima m. Br J Pharmacol. 1999 Feb;126(3):613-20. doi: 10.1038/sj.bjp.0702340. Br J Pharmacol. 1999. PMID: 10188971 Free PMC article.

7

Early increases in renal kallikrein secretion on administration of potassium or ATP-sensitive potassium channel blockers in rats.

Fujita T, Hayashi I, Kumagai Y, Inamura N, Majima M. Fujita T, et al. Among authors: majima m. Br J Pharmacol. 1999 Nov;128(6):1275-83. doi: 10.1038/sj.bjp.0702899. Br J Pharmacol. 1999. PMID: 10578142 Free PMC article.

8

A secretory mechanism of renal kallikrein by a high potassium ion; a possible involvement of ATP-sensitive potassium channel.

Hayashi I, Fujita T, Majima M, Katori M. Hayashi I, et al. Among authors: majima m. Immunopharmacology. 1999 Oct 15;44(1-2):49-55. doi: 10.1016/s0162-3109(99)00110-1. Immunopharmacology. 1999. PMID: 10604524

9

Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention.

Majima M, Hayashi I, Fujita T, Ito H, Nakajima S, Katori M. Majima M, et al. Immunopharmacology. 1999 Oct 15;44(1-2):145-52. doi: 10.1016/s0162-3109(99)00086-7. Immunopharmacology. 1999. PMID: 10604538

10

K+ loading, but not Na+ loading, and blockade of ATP-sensitive K+ channels augment renal kallikrein secretion.

Fujita T, Hayashi I, Kumagai Y, Inamura N, Majima M. Fujita T, et al. Among authors: majima m. Immunopharmacology. 1999 Oct 15;44(1-2):169-75. doi: 10.1016/s0162-3109(99)00088-0. Immunopharmacology. 1999. PMID: 10604541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters